Newron Rises After Parkinson’s Drug Study Succeeds

Newron Pharmaceuticals SpA, an Italian developer of an experimental treatment for Parkinson’s disease, rose to the highest in almost six weeks after saying the drug succeeded in two clinical trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.